AbbVie combines advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people’s lives. Read through our press releases to see our latest efforts to improve patient care.

If you are a member of the news media and have questions or need additional information, please contact our Communications Team.

May 24, 2018

IMBRUVICA® (ibrutinib) Plus GAZYVA® (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint

NORTH CHICAGO, Ill., May 24, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the Phase 3 iLLUMINATE (PCYC-1130) trial met its primary endpoint of improvement in progression-free survival (PFS). The study evaluated IMBRUVICA® (ibrutinib) in combination with GAZYVA® (obinutuzumab) in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) patients, the most common adult leukemia. Specifically, the study met its primary endpoint for a clinically and statistically significant difference in PFS for patients treated with IMBRUVICA plus obinutuzumab versus those who received chlorambucil plus obinutuzumab, as assessed by an Independent Review Committee (IRC).

May 22, 2018

AbbVie Donates $100 Million to Strengthen Access to Healthcare, Housing for Hurricane-Ravaged Puerto Rico

NORTH CHICAGO, Ill., May 22, 2018 /PRNewswire/ -- AbbVie, a research-based global biopharmaceutical company, today announced a donation of $100 million to two organizations, Direct Relief and Habitat for Humanity International, to strengthen access to healthcare and housing in Puerto Rico. The organizations will receive $50 million each. This donation is an extension of the more than $4 million AbbVie provided following the unprecedented natural disasters of 2017.

Spanish version available.

May 22, 2018

AbbVie to Present at the Jefferies 2018 Global Healthcare Conference

NORTH CHICAGO, Ill., May 22, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Jefferies 2018 Global Healthcare Conference on Wednesday, June 6, 2018. Bill Chase, executive vice president and chief financial officer, will present at 7:30 a.m. Central time.

May 16, 2018

AbbVie to Show Progress and Growth in Oncology Research at the American Society of Clinical Oncology 2018 Annual Meeting

NORTH CHICAGO, Ill., May 16, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced it will present data about the company's portfolio of investigational oncology medicines during the American Society of Clinical Oncology (ASCO) Annual Meeting, June 1-5, in Chicago. More than 30 abstracts have been accepted, featuring data in hematologic malignancies and several solid tumor types, including brain cancer and lung cancer. 

May 08, 2018

AbbVie to Present at the UBS Global Healthcare Conference

NORTH CHICAGO, Ill., May 8, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the UBS Global Healthcare Conference on Tuesday, May 22, 2018. Bill Chase, executive vice president and chief financial officer, will present at 7:30 a.m. Central time.

May 02, 2018

AbbVie to Present at the 2018 Bank of America Merrill Lynch Health Care Conference

NORTH CHICAGO, Ill., May 2, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the 2018 Bank of America Merrill Lynch Health Care Conference on Wednesday, May 16, 2018. Richard A. Gonzalez, chairman and chief executive officer, will present at 6:20 p.m. Central time.

May 01, 2018

AbbVie Submits Marketing Authorization Application to the European Medicines Agency for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis

NORTH CHICAGO, Ill., May 1, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced that it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for risankizumab, an investigational interleukin-23 (IL-23) inhibitor, being evaluated for the treatment of patients with moderate to severe plaque psoriasis.

May 01, 2018

AbbVie Commences Self-Tender Offer for Up to $7.5 Billion of its Common Stock

NORTH CHICAGO, Ill., May 1, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has commenced a modified "Dutch auction" tender offer to purchase for cash up to $7.5 billion of its common stock at a price not less than $99.00 per share and not more than $114.00 per share.

Apr 30, 2018

AbbVie and Rice University establish K.C. Nicolaou Research Accelerator to advance therapies in oncology

NORTH CHICAGO, Ill. and HOUSTON, April 30, 2018 /PRNewswire/ -- AbbVie, a research-based global biopharmaceutical company, and Rice University today announced they have entered into a joint research collaboration to establish the K.C. Nicolaou Research Accelerator. The research at the Accelerator will focus on synthesizing novel cytotoxic agents for use in the fight against cancer. The collaboration will complement AbbVie's existing expertise in oncology discovery and early development.

Apr 27, 2018

AbbVie Presents New Investigational Data for Elagolix at the 2018 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting

NORTH CHICAGO, Ill., April 27, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today announced that data  for elagolix, an investigational, orally administered gonadotropin-releasing hormone (GnRH) receptor antagonist, will be presented at the 2018 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting in Austin, TX.